Unlocking the Potential of AI-Driven Comprehensive Genomic Profiling with Absolute SoLiQ
4baseCare, in collaboration with Cellworks, has introduced AI-driven personalized cancer care to India with Absolute SoLiQ. This advanced solution combines AI/ML Biosimulation to deliver a comprehensive analysis of ~20,000 genes from whole-exome DNA and RNA profiling (tissue), ~20,000 genes from germline DNA (blood), and 1,212 genes from liquid biopsy (ctDNA). This integrated approach guides optimal therapy selection based on actionable genomic biomarkers and pathway analysis, providing a truly personalized treatment strategy
Leveraging Cellworks' proprietary Therapy Response Index (TRI) and Pathway Analysis algorithms within the Cellworks Ventura™ report, oncologists can identify the most effective treatment strategies tailored to each patient’s unique genomic profile, resulting in improved clinical outcomes.
Absolute SoLiQintegrates NGS analysis from solid biopsy (tumor tissue), liquid biopsy (ctDNA), and whole blood (germline DNA), offering a 360° view of the disease.This dual-source approach mitigates the limitations of each biopsy method and provides optimal disease resolution, enabling better-informed clinical decision-making.
Ultimately, SoLiQ and AI-driven CGP enable true personalization of cancer treatment, making it a transformative tool in solid cancer management.
Benefits of Absolute SoLiQ Gene Panel Testing
Therapy prediction
This gene panel generates an in-depth report based on the whole-exome DNA and RNA profiling by leveraging AI and machine learning algorithms. This report includes the Cellworks proprietary Therapy Response Index (TRI) and Pathway Analysis.
Solid and liquid biopsy integration
This comprehensive approach identifies true somatic mutations and enables parallel tissue DNA/RNA and ctDNA analysis. As a result, it facilitates optimal disease resolution.
Personalized treatment selection
By combining the insights from comprehensive genomic analysis and therapy prediction, this gene panel empowers oncologists to personalize cancer treatment plans. The information provided in the report helps guide clinicians in selecting the most appropriate therapies and combinations tailored to each patient’s unique genomic profile.
Improved clinical outcomes
Enhances treatment decision-making and facilitates targeted therapy selection that leads to improved treatment efficacy, reduced adverse effects, and better patient outcomes.
Why Choose 4baseCare's Absolute SoLiQ Cancer Gene Panel?
Comprehensive Analysis
Our Cancer Gene Panel thoroughly assesses clinically relevant genes, ensuring accurate and reliable results.
Advanced Technology
We utilize cutting-edge next generation sequencing technology to deliver precise and detailed genetic information.
Expert Team
Our team of experienced genetic counselors and healthcare professionals will guide you through the testing process, answer your questions, and help you understand the implications of the results.
Confidentiality and Privacy
We adhere to strict privacy protocols and maintain the confidentiality of your genetic information.
Get Started Now by Requesting Your Test
Resources
Explore 4baseCare Solutions
Kindly fill the form below to download our TARGT Absolute Pro Portfolio Brochure :
Consult our Genetic Counselor to find the right test for you.
Fill the form below and we will contact you shortly.
Thank you for reaching out to us. Our team will get in touch with you shortly.
Kindly fill the form below to download our Liquid Biopsy Portfolio brochure :
Kindly fill the form below to download our TARGT Portfolio Brochure
Kindly fill the form below to download our TARGT Core Gene List